nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Pain in jaw—Vincristine—muscle cancer	0.0434	0.0434	CcSEcCtD
Regadenoson—Altered state of consciousness—Vincristine—muscle cancer	0.0306	0.0306	CcSEcCtD
Regadenoson—Bronchial hyperreactivity—Methotrexate—muscle cancer	0.0263	0.0263	CcSEcCtD
Regadenoson—Electrocardiogram ST segment depression—Doxorubicin—muscle cancer	0.0262	0.0262	CcSEcCtD
Regadenoson—Chronic obstructive pulmonary disease—Methotrexate—muscle cancer	0.024	0.024	CcSEcCtD
Regadenoson—Throat tightness—Etoposide—muscle cancer	0.0234	0.0234	CcSEcCtD
Regadenoson—Respiratory distress—Vincristine—muscle cancer	0.0223	0.0223	CcSEcCtD
Regadenoson—Musculoskeletal pain—Vincristine—muscle cancer	0.0143	0.0143	CcSEcCtD
Regadenoson—Chest discomfort—Etoposide—muscle cancer	0.013	0.013	CcSEcCtD
Regadenoson—Pain in extremity—Vincristine—muscle cancer	0.0103	0.0103	CcSEcCtD
Regadenoson—Cardiac arrest—Vincristine—muscle cancer	0.00976	0.00976	CcSEcCtD
Regadenoson—Ventricular arrhythmia—Doxorubicin—muscle cancer	0.00803	0.00803	CcSEcCtD
Regadenoson—Cardiac arrest—Etoposide—muscle cancer	0.00791	0.00791	CcSEcCtD
Regadenoson—Acute coronary syndrome—Vincristine—muscle cancer	0.0078	0.0078	CcSEcCtD
Regadenoson—Myocardial infarction—Vincristine—muscle cancer	0.00776	0.00776	CcSEcCtD
Regadenoson—Feeling hot—Doxorubicin—muscle cancer	0.00757	0.00757	CcSEcCtD
Regadenoson—Flushing—Dactinomycin—muscle cancer	0.00738	0.00738	CcSEcCtD
Regadenoson—Injection site pain—Doxorubicin—muscle cancer	0.00728	0.00728	CcSEcCtD
Regadenoson—Bronchospasm—Etoposide—muscle cancer	0.00707	0.00707	CcSEcCtD
Regadenoson—Hypoaesthesia—Vincristine—muscle cancer	0.00707	0.00707	CcSEcCtD
Regadenoson—Connective tissue disorder—Vincristine—muscle cancer	0.00698	0.00698	CcSEcCtD
Regadenoson—Erythema—Dactinomycin—muscle cancer	0.00692	0.00692	CcSEcCtD
Regadenoson—Vasodilation—Doxorubicin—muscle cancer	0.00676	0.00676	CcSEcCtD
Regadenoson—Vasodilation procedure—Doxorubicin—muscle cancer	0.00676	0.00676	CcSEcCtD
Regadenoson—Depressed level of consciousness—Methotrexate—muscle cancer	0.00663	0.00663	CcSEcCtD
Regadenoson—Cardiac disorder—Vincristine—muscle cancer	0.00659	0.00659	CcSEcCtD
Regadenoson—Angiopathy—Vincristine—muscle cancer	0.00645	0.00645	CcSEcCtD
Regadenoson—Ill-defined disorder—Dactinomycin—muscle cancer	0.00642	0.00642	CcSEcCtD
Regadenoson—Mediastinal disorder—Vincristine—muscle cancer	0.0064	0.0064	CcSEcCtD
Regadenoson—Acute coronary syndrome—Etoposide—muscle cancer	0.00632	0.00632	CcSEcCtD
Regadenoson—Renal failure—Etoposide—muscle cancer	0.0063	0.0063	CcSEcCtD
Regadenoson—Myocardial infarction—Etoposide—muscle cancer	0.00628	0.00628	CcSEcCtD
Regadenoson—Malaise—Dactinomycin—muscle cancer	0.00624	0.00624	CcSEcCtD
Regadenoson—Mental disorder—Vincristine—muscle cancer	0.00622	0.00622	CcSEcCtD
Regadenoson—Atrioventricular block—Doxorubicin—muscle cancer	0.00613	0.00613	CcSEcCtD
Regadenoson—Musculoskeletal pain—Doxorubicin—muscle cancer	0.00602	0.00602	CcSEcCtD
Regadenoson—Myalgia—Dactinomycin—muscle cancer	0.00589	0.00589	CcSEcCtD
Regadenoson—Discomfort—Dactinomycin—muscle cancer	0.00582	0.00582	CcSEcCtD
Regadenoson—Hypoaesthesia—Etoposide—muscle cancer	0.00573	0.00573	CcSEcCtD
Regadenoson—Eye disorder—Etoposide—muscle cancer	0.00538	0.00538	CcSEcCtD
Regadenoson—Convulsion—Vincristine—muscle cancer	0.00536	0.00536	CcSEcCtD
Regadenoson—Flushing—Etoposide—muscle cancer	0.00534	0.00534	CcSEcCtD
Regadenoson—Cardiac disorder—Etoposide—muscle cancer	0.00534	0.00534	CcSEcCtD
Regadenoson—Hypertension—Vincristine—muscle cancer	0.00534	0.00534	CcSEcCtD
Regadenoson—Myalgia—Vincristine—muscle cancer	0.00526	0.00526	CcSEcCtD
Regadenoson—Angiopathy—Etoposide—muscle cancer	0.00522	0.00522	CcSEcCtD
Regadenoson—Immune system disorder—Etoposide—muscle cancer	0.0052	0.0052	CcSEcCtD
Regadenoson—Mediastinal disorder—Etoposide—muscle cancer	0.00519	0.00519	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00515	0.00515	CcSEcCtD
Regadenoson—Cerebrovascular accident—Methotrexate—muscle cancer	0.00508	0.00508	CcSEcCtD
Regadenoson—Anaphylactic shock—Vincristine—muscle cancer	0.00505	0.00505	CcSEcCtD
Regadenoson—Nervous system disorder—Vincristine—muscle cancer	0.00495	0.00495	CcSEcCtD
Regadenoson—Dysgeusia—Etoposide—muscle cancer	0.00491	0.00491	CcSEcCtD
Regadenoson—Hyperhidrosis—Vincristine—muscle cancer	0.00488	0.00488	CcSEcCtD
Regadenoson—Pain—Dactinomycin—muscle cancer	0.00483	0.00483	CcSEcCtD
Regadenoson—Eye pain—Doxorubicin—muscle cancer	0.00478	0.00478	CcSEcCtD
Regadenoson—Hypotension—Vincristine—muscle cancer	0.00472	0.00472	CcSEcCtD
Regadenoson—Feeling abnormal—Dactinomycin—muscle cancer	0.00465	0.00465	CcSEcCtD
Regadenoson—Ill-defined disorder—Etoposide—muscle cancer	0.00465	0.00465	CcSEcCtD
Regadenoson—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00462	0.00462	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Vincristine—muscle cancer	0.0046	0.0046	CcSEcCtD
Regadenoson—Insomnia—Vincristine—muscle cancer	0.00456	0.00456	CcSEcCtD
Regadenoson—Renal impairment—Doxorubicin—muscle cancer	0.00453	0.00453	CcSEcCtD
Regadenoson—Paraesthesia—Vincristine—muscle cancer	0.00453	0.00453	CcSEcCtD
Regadenoson—Malaise—Etoposide—muscle cancer	0.00452	0.00452	CcSEcCtD
Regadenoson—Abdominal pain—Dactinomycin—muscle cancer	0.00447	0.00447	CcSEcCtD
Regadenoson—Loss of consciousness—Etoposide—muscle cancer	0.0044	0.0044	CcSEcCtD
Regadenoson—Cerebrovascular accident—Doxorubicin—muscle cancer	0.0044	0.0044	CcSEcCtD
Regadenoson—Cough—Etoposide—muscle cancer	0.00437	0.00437	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Vincristine—muscle cancer	0.00436	0.00436	CcSEcCtD
Regadenoson—Convulsion—Etoposide—muscle cancer	0.00434	0.00434	CcSEcCtD
Regadenoson—Hypertension—Etoposide—muscle cancer	0.00432	0.00432	CcSEcCtD
Regadenoson—Pain—Vincristine—muscle cancer	0.00432	0.00432	CcSEcCtD
Regadenoson—Pain in extremity—Doxorubicin—muscle cancer	0.00431	0.00431	CcSEcCtD
Regadenoson—Asthma—Methotrexate—muscle cancer	0.00431	0.00431	CcSEcCtD
Regadenoson—Chest pain—Etoposide—muscle cancer	0.00426	0.00426	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00424	0.00424	CcSEcCtD
Regadenoson—Discomfort—Etoposide—muscle cancer	0.00421	0.00421	CcSEcCtD
Regadenoson—Hypersensitivity—Dactinomycin—muscle cancer	0.00416	0.00416	CcSEcCtD
Regadenoson—Abdominal discomfort—Methotrexate—muscle cancer	0.00413	0.00413	CcSEcCtD
Regadenoson—Gastrointestinal pain—Vincristine—muscle cancer	0.00413	0.00413	CcSEcCtD
Regadenoson—Cardiac arrest—Doxorubicin—muscle cancer	0.0041	0.0041	CcSEcCtD
Regadenoson—Anaphylactic shock—Etoposide—muscle cancer	0.00409	0.00409	CcSEcCtD
Regadenoson—Asthenia—Dactinomycin—muscle cancer	0.00405	0.00405	CcSEcCtD
Regadenoson—Tachycardia—Etoposide—muscle cancer	0.00399	0.00399	CcSEcCtD
Regadenoson—Abdominal pain—Vincristine—muscle cancer	0.00399	0.00399	CcSEcCtD
Regadenoson—Skin disorder—Etoposide—muscle cancer	0.00397	0.00397	CcSEcCtD
Regadenoson—Hyperhidrosis—Etoposide—muscle cancer	0.00395	0.00395	CcSEcCtD
Regadenoson—Diarrhoea—Dactinomycin—muscle cancer	0.00386	0.00386	CcSEcCtD
Regadenoson—Hypotension—Etoposide—muscle cancer	0.00382	0.00382	CcSEcCtD
Regadenoson—Renal failure—Methotrexate—muscle cancer	0.00377	0.00377	CcSEcCtD
Regadenoson—Abdominal distension—Doxorubicin—muscle cancer	0.00375	0.00375	CcSEcCtD
Regadenoson—Asthma—Doxorubicin—muscle cancer	0.00373	0.00373	CcSEcCtD
Regadenoson—Hypersensitivity—Vincristine—muscle cancer	0.00372	0.00372	CcSEcCtD
Regadenoson—Paraesthesia—Etoposide—muscle cancer	0.00367	0.00367	CcSEcCtD
Regadenoson—Dyspnoea—Etoposide—muscle cancer	0.00364	0.00364	CcSEcCtD
Regadenoson—Somnolence—Etoposide—muscle cancer	0.00363	0.00363	CcSEcCtD
Regadenoson—Angina pectoris—Doxorubicin—muscle cancer	0.00363	0.00363	CcSEcCtD
Regadenoson—Asthenia—Vincristine—muscle cancer	0.00362	0.00362	CcSEcCtD
Regadenoson—Vomiting—Dactinomycin—muscle cancer	0.00359	0.00359	CcSEcCtD
Regadenoson—Rash—Dactinomycin—muscle cancer	0.00356	0.00356	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Etoposide—muscle cancer	0.00353	0.00353	CcSEcCtD
Regadenoson—Pain—Etoposide—muscle cancer	0.0035	0.0035	CcSEcCtD
Regadenoson—Diarrhoea—Vincristine—muscle cancer	0.00345	0.00345	CcSEcCtD
Regadenoson—Feeling abnormal—Etoposide—muscle cancer	0.00337	0.00337	CcSEcCtD
Regadenoson—Nausea—Dactinomycin—muscle cancer	0.00336	0.00336	CcSEcCtD
Regadenoson—Gastrointestinal pain—Etoposide—muscle cancer	0.00334	0.00334	CcSEcCtD
Regadenoson—Dizziness—Vincristine—muscle cancer	0.00334	0.00334	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—muscle cancer	0.00327	0.00327	CcSEcCtD
Regadenoson—Urticaria—Etoposide—muscle cancer	0.00325	0.00325	CcSEcCtD
Regadenoson—Abdominal pain—Etoposide—muscle cancer	0.00323	0.00323	CcSEcCtD
Regadenoson—Eye disorder—Methotrexate—muscle cancer	0.00322	0.00322	CcSEcCtD
Regadenoson—Tinnitus—Methotrexate—muscle cancer	0.00321	0.00321	CcSEcCtD
Regadenoson—Vomiting—Vincristine—muscle cancer	0.00321	0.00321	CcSEcCtD
Regadenoson—Cardiac disorder—Methotrexate—muscle cancer	0.0032	0.0032	CcSEcCtD
Regadenoson—Rash—Vincristine—muscle cancer	0.00318	0.00318	CcSEcCtD
Regadenoson—Dermatitis—Vincristine—muscle cancer	0.00318	0.00318	CcSEcCtD
Regadenoson—Headache—Vincristine—muscle cancer	0.00316	0.00316	CcSEcCtD
Regadenoson—Angiopathy—Methotrexate—muscle cancer	0.00313	0.00313	CcSEcCtD
Regadenoson—Immune system disorder—Methotrexate—muscle cancer	0.00311	0.00311	CcSEcCtD
Regadenoson—Mediastinal disorder—Methotrexate—muscle cancer	0.00311	0.00311	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—muscle cancer	0.00304	0.00304	CcSEcCtD
Regadenoson—Mental disorder—Methotrexate—muscle cancer	0.00302	0.00302	CcSEcCtD
Regadenoson—Hypersensitivity—Etoposide—muscle cancer	0.00301	0.00301	CcSEcCtD
Regadenoson—Erythema—Methotrexate—muscle cancer	0.003	0.003	CcSEcCtD
Regadenoson—Nausea—Vincristine—muscle cancer	0.003	0.003	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—muscle cancer	0.00297	0.00297	CcSEcCtD
Regadenoson—Dysgeusia—Methotrexate—muscle cancer	0.00294	0.00294	CcSEcCtD
Regadenoson—Asthenia—Etoposide—muscle cancer	0.00293	0.00293	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—muscle cancer	0.00293	0.00293	CcSEcCtD
Regadenoson—Vision blurred—Methotrexate—muscle cancer	0.00283	0.00283	CcSEcCtD
Regadenoson—Diarrhoea—Etoposide—muscle cancer	0.0028	0.0028	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—muscle cancer	0.00279	0.00279	CcSEcCtD
Regadenoson—Ill-defined disorder—Methotrexate—muscle cancer	0.00278	0.00278	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—muscle cancer	0.00278	0.00278	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—muscle cancer	0.00277	0.00277	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—muscle cancer	0.00277	0.00277	CcSEcCtD
Regadenoson—Angiopathy—Doxorubicin—muscle cancer	0.00271	0.00271	CcSEcCtD
Regadenoson—Malaise—Methotrexate—muscle cancer	0.00271	0.00271	CcSEcCtD
Regadenoson—Dizziness—Etoposide—muscle cancer	0.0027	0.0027	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—muscle cancer	0.0027	0.0027	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—muscle cancer	0.00269	0.00269	CcSEcCtD
Regadenoson—Cough—Methotrexate—muscle cancer	0.00262	0.00262	CcSEcCtD
Regadenoson—Mental disorder—Doxorubicin—muscle cancer	0.00261	0.00261	CcSEcCtD
Regadenoson—Convulsion—Methotrexate—muscle cancer	0.0026	0.0026	CcSEcCtD
Regadenoson—Vomiting—Etoposide—muscle cancer	0.0026	0.0026	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—muscle cancer	0.0026	0.0026	CcSEcCtD
Regadenoson—Rash—Etoposide—muscle cancer	0.00258	0.00258	CcSEcCtD
Regadenoson—Dermatitis—Etoposide—muscle cancer	0.00258	0.00258	CcSEcCtD
Regadenoson—Headache—Etoposide—muscle cancer	0.00256	0.00256	CcSEcCtD
Regadenoson—Chest pain—Methotrexate—muscle cancer	0.00255	0.00255	CcSEcCtD
Regadenoson—Myalgia—Methotrexate—muscle cancer	0.00255	0.00255	CcSEcCtD
Regadenoson—Arthralgia—Methotrexate—muscle cancer	0.00255	0.00255	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—muscle cancer	0.00254	0.00254	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00254	0.00254	CcSEcCtD
Regadenoson—Discomfort—Methotrexate—muscle cancer	0.00252	0.00252	CcSEcCtD
Regadenoson—Anaphylactic shock—Methotrexate—muscle cancer	0.00245	0.00245	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—muscle cancer	0.00245	0.00245	CcSEcCtD
Regadenoson—Nausea—Etoposide—muscle cancer	0.00243	0.00243	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—muscle cancer	0.00241	0.00241	CcSEcCtD
Regadenoson—Nervous system disorder—Methotrexate—muscle cancer	0.0024	0.0024	CcSEcCtD
Regadenoson—Skin disorder—Methotrexate—muscle cancer	0.00238	0.00238	CcSEcCtD
Regadenoson—Hyperhidrosis—Methotrexate—muscle cancer	0.00237	0.00237	CcSEcCtD
Regadenoson—Malaise—Doxorubicin—muscle cancer	0.00234	0.00234	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—muscle cancer	0.00233	0.00233	CcSEcCtD
Regadenoson—Palpitations—Doxorubicin—muscle cancer	0.0023	0.0023	CcSEcCtD
Regadenoson—Hypotension—Methotrexate—muscle cancer	0.00229	0.00229	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—muscle cancer	0.00228	0.00228	CcSEcCtD
Regadenoson—Cough—Doxorubicin—muscle cancer	0.00227	0.00227	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—muscle cancer	0.00225	0.00225	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—muscle cancer	0.00224	0.00224	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00223	0.00223	CcSEcCtD
Regadenoson—Insomnia—Methotrexate—muscle cancer	0.00221	0.00221	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—muscle cancer	0.00221	0.00221	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—muscle cancer	0.00221	0.00221	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—muscle cancer	0.00221	0.00221	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—muscle cancer	0.0022	0.0022	CcSEcCtD
Regadenoson—Paraesthesia—Methotrexate—muscle cancer	0.0022	0.0022	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.0022	0.0022	CcSEcCtD
Regadenoson—Discomfort—Doxorubicin—muscle cancer	0.00219	0.00219	CcSEcCtD
Regadenoson—Dyspnoea—Methotrexate—muscle cancer	0.00218	0.00218	CcSEcCtD
Regadenoson—Somnolence—Methotrexate—muscle cancer	0.00218	0.00218	CcSEcCtD
Regadenoson—Anaphylactic shock—Doxorubicin—muscle cancer	0.00212	0.00212	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00211	0.00211	CcSEcCtD
Regadenoson—Pain—Methotrexate—muscle cancer	0.00209	0.00209	CcSEcCtD
Regadenoson—Shock—Doxorubicin—muscle cancer	0.00209	0.00209	CcSEcCtD
Regadenoson—Nervous system disorder—Doxorubicin—muscle cancer	0.00208	0.00208	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—muscle cancer	0.00207	0.00207	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—muscle cancer	0.00206	0.00206	CcSEcCtD
Regadenoson—Hyperhidrosis—Doxorubicin—muscle cancer	0.00205	0.00205	CcSEcCtD
Regadenoson—Feeling abnormal—Methotrexate—muscle cancer	0.00202	0.00202	CcSEcCtD
Regadenoson—Gastrointestinal pain—Methotrexate—muscle cancer	0.002	0.002	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—muscle cancer	0.00198	0.00198	CcSEcCtD
Regadenoson—Urticaria—Methotrexate—muscle cancer	0.00195	0.00195	CcSEcCtD
Regadenoson—Abdominal pain—Methotrexate—muscle cancer	0.00194	0.00194	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00193	0.00193	CcSEcCtD
Regadenoson—Insomnia—Doxorubicin—muscle cancer	0.00192	0.00192	CcSEcCtD
Regadenoson—Paraesthesia—Doxorubicin—muscle cancer	0.0019	0.0019	CcSEcCtD
Regadenoson—Dyspnoea—Doxorubicin—muscle cancer	0.00189	0.00189	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—muscle cancer	0.00189	0.00189	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00183	0.00183	CcSEcCtD
Regadenoson—Pain—Doxorubicin—muscle cancer	0.00181	0.00181	CcSEcCtD
Regadenoson—Hypersensitivity—Methotrexate—muscle cancer	0.0018	0.0018	CcSEcCtD
Regadenoson—Asthenia—Methotrexate—muscle cancer	0.00176	0.00176	CcSEcCtD
Regadenoson—Feeling abnormal—Doxorubicin—muscle cancer	0.00175	0.00175	CcSEcCtD
Regadenoson—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00173	0.00173	CcSEcCtD
Regadenoson—Urticaria—Doxorubicin—muscle cancer	0.00168	0.00168	CcSEcCtD
Regadenoson—Abdominal pain—Doxorubicin—muscle cancer	0.00168	0.00168	CcSEcCtD
Regadenoson—Diarrhoea—Methotrexate—muscle cancer	0.00168	0.00168	CcSEcCtD
Regadenoson—Dizziness—Methotrexate—muscle cancer	0.00162	0.00162	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—muscle cancer	0.00156	0.00156	CcSEcCtD
Regadenoson—Vomiting—Methotrexate—muscle cancer	0.00156	0.00156	CcSEcCtD
Regadenoson—Rash—Methotrexate—muscle cancer	0.00154	0.00154	CcSEcCtD
Regadenoson—Dermatitis—Methotrexate—muscle cancer	0.00154	0.00154	CcSEcCtD
Regadenoson—Headache—Methotrexate—muscle cancer	0.00153	0.00153	CcSEcCtD
Regadenoson—Asthenia—Doxorubicin—muscle cancer	0.00152	0.00152	CcSEcCtD
Regadenoson—Nausea—Methotrexate—muscle cancer	0.00145	0.00145	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—muscle cancer	0.00145	0.00145	CcSEcCtD
Regadenoson—Dizziness—Doxorubicin—muscle cancer	0.0014	0.0014	CcSEcCtD
Regadenoson—Vomiting—Doxorubicin—muscle cancer	0.00135	0.00135	CcSEcCtD
Regadenoson—Rash—Doxorubicin—muscle cancer	0.00134	0.00134	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—muscle cancer	0.00134	0.00134	CcSEcCtD
Regadenoson—Headache—Doxorubicin—muscle cancer	0.00133	0.00133	CcSEcCtD
Regadenoson—Nausea—Doxorubicin—muscle cancer	0.00126	0.00126	CcSEcCtD
